CN1553771A - 含烟碱的口服剂量形式 - Google Patents

含烟碱的口服剂量形式 Download PDF

Info

Publication number
CN1553771A
CN1553771A CNA028073339A CN02807333A CN1553771A CN 1553771 A CN1553771 A CN 1553771A CN A028073339 A CNA028073339 A CN A028073339A CN 02807333 A CN02807333 A CN 02807333A CN 1553771 A CN1553771 A CN 1553771A
Authority
CN
China
Prior art keywords
nicotine
dosage form
active substance
weight
sugar alcohol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA028073339A
Other languages
English (en)
Chinese (zh)
Inventor
J・刘
J·刘
莱赫
S·J·莱赫
特考
S·普拉特考
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of CN1553771A publication Critical patent/CN1553771A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/465—Nicotine; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Psychiatry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
CNA028073339A 2001-03-26 2002-03-22 含烟碱的口服剂量形式 Pending CN1553771A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US27860601P 2001-03-26 2001-03-26
US60/278,606 2001-03-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNA2008101253651A Division CN101301275A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式的制备方法

Publications (1)

Publication Number Publication Date
CN1553771A true CN1553771A (zh) 2004-12-08

Family

ID=23065632

Family Applications (2)

Application Number Title Priority Date Filing Date
CNA028073339A Pending CN1553771A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式
CNA2008101253651A Pending CN101301275A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式的制备方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNA2008101253651A Pending CN101301275A (zh) 2001-03-26 2002-03-22 含烟碱的口服剂量形式的制备方法

Country Status (11)

Country Link
EP (1) EP1372392A4 (enExample)
JP (1) JP2004525928A (enExample)
CN (2) CN1553771A (enExample)
AR (1) AR033444A1 (enExample)
AU (1) AU2002252470B2 (enExample)
BR (1) BR0208382A (enExample)
CA (1) CA2440713A1 (enExample)
MX (1) MXPA03008762A (enExample)
NZ (1) NZ528167A (enExample)
PL (1) PL364621A1 (enExample)
WO (1) WO2002076211A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110621307A (zh) * 2017-05-30 2019-12-27 伊诺拉玛制药公司 含有烟碱的口香糖组合物

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253307A1 (en) * 2003-02-04 2004-12-16 Brian Hague Sugar-free oral transmucosal solid dosage forms and uses thereof
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
PL2446881T3 (pl) * 2003-07-24 2014-08-29 Glaxosmithkline Llc Folie rozpuszczające się w jamie ustnej
GB0320854D0 (en) 2003-09-05 2003-10-08 Arrow No 7 Ltd Buccal drug delivery
US20070191815A1 (en) 2004-09-13 2007-08-16 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery
CN104397869B (zh) 2003-11-07 2016-06-08 美国无烟烟草有限责任公司 烟草组合物
US8627828B2 (en) 2003-11-07 2014-01-14 U.S. Smokeless Tobacco Company Llc Tobacco compositions
BRPI0514283A (pt) * 2004-08-11 2008-06-10 Cadbury Adams Usa Llc composições para aquecimento e sistemas de liberação para as mesmas
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
MX2009005671A (es) * 2006-12-01 2009-06-08 Cima Labs Inc Forma de dosificacion de nicotina transmucosal oral.
GB2468424B (en) * 2007-04-02 2011-11-09 Parkinson S Inst Methods and compositions for reduction of side effects of therapeutic treatments
ES2521494T3 (es) 2007-04-02 2014-11-12 Parkinson's Institute Métodos y composiciones para la reducción de los efectos secundarios de tratamientos terapéuticos
DE102008012015A1 (de) * 2008-03-01 2009-09-10 Südzucker AG Mannheim/Ochsenfurt Verbesserte Isomalt-haltige Komprimate und Verfahren zu ihrer Herstellung
MX2012009586A (es) * 2010-02-18 2012-09-12 Jatin Vasant Thakkar Patillas de gelatina blanda con nicotina.
US20110274628A1 (en) 2010-05-07 2011-11-10 Borschke August J Nicotine-containing pharmaceutical compositions
UA112974C2 (uk) * 2010-09-16 2016-11-25 Джеі. Бі. Кемікалс Енд Фармасьютікалс Лімітид Нікотиновмісна композиція (варіанти)
US20130017259A1 (en) 2011-07-06 2013-01-17 The Parkinson's Institute Compositions and Methods for Treatment of Symptoms in Parkinson's Disease Patients
US9629392B2 (en) 2011-09-22 2017-04-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9084439B2 (en) 2011-09-22 2015-07-21 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US20130078307A1 (en) 2011-09-22 2013-03-28 Niconovum Usa, Inc. Nicotine-containing pharmaceutical composition
US9474303B2 (en) * 2011-09-22 2016-10-25 R.J. Reynolds Tobacco Company Translucent smokeless tobacco product
US9907748B2 (en) 2011-10-21 2018-03-06 Niconovum Usa, Inc. Excipients for nicotine-containing therapeutic compositions
US9044035B2 (en) * 2012-04-17 2015-06-02 R.J. Reynolds Tobacco Company Remelted ingestible products
AR096223A1 (es) * 2013-05-10 2015-12-16 Glaxosmithkline Llc Pastilla de nicotina para administración oral
CN104132895B (zh) * 2014-07-08 2017-08-25 国家烟草质量监督检验中心 适用于连续流动法测定烟草及烟草制品中总植物碱的缓冲体系
WO2016123406A1 (en) 2015-01-28 2016-08-04 Chrono Therapeutics Inc. Drug delivery methods and systems
EP3267875A4 (en) 2015-03-12 2018-12-05 Chrono Therapeutics Inc. Craving input and support system
WO2018129304A1 (en) 2017-01-06 2018-07-12 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
CA3101966A1 (en) 2018-05-29 2019-12-05 Morningside Venture Investments Limited Drug delivery methods and systems
US12397141B2 (en) 2018-11-16 2025-08-26 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system
DK3826477T3 (da) * 2019-06-07 2023-12-11 Philip Morris Products Sa Poseprodukt med flydende smagssammensætning
CA3167882A1 (en) * 2020-01-15 2021-07-22 Mcneil Ab Lozenge
USD1081739S1 (en) 2021-04-06 2025-07-01 Altria Client Services Llc Die for gum forming
US20220313678A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Spray dried nicotine for inclusion in oral products
US20220313614A1 (en) * 2021-04-06 2022-10-06 Altria Client Services Llc Encapsulated nicotine granules and methods of preparation thereof
US12295412B2 (en) 2022-01-28 2025-05-13 Altria Client Services Llc Oral pouch product

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310412D0 (en) * 1993-05-20 1993-07-07 Danbiosyst Uk Nasal nicotine system
US5549906A (en) * 1993-07-26 1996-08-27 Pharmacia Ab Nicotine lozenge and therapeutic method for smoking cessation
US5362496A (en) * 1993-08-04 1994-11-08 Pharmetrix Corporation Method and therapeutic system for smoking cessation
DE19536394A1 (de) * 1995-09-29 1997-04-03 Basf Ag Feste Arzneiformen, erhältlich durch Extrusion einer Isomalt enthaltenden Polymer-Wirkstoff-Schmelze
DE19639342C2 (de) * 1996-09-25 1998-07-16 Suedzucker Ag Kaugummi, enthaltend ein Süßungsmittel
US6322806B1 (en) * 1999-04-06 2001-11-27 Wm. Wrigley Jr. Company Over-coated chewing gum formulations including tableted center

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110621307A (zh) * 2017-05-30 2019-12-27 伊诺拉玛制药公司 含有烟碱的口香糖组合物

Also Published As

Publication number Publication date
NZ528167A (en) 2005-04-29
PL364621A1 (en) 2004-12-13
JP2004525928A (ja) 2004-08-26
CN101301275A (zh) 2008-11-12
BR0208382A (pt) 2004-06-15
WO2002076211A1 (en) 2002-10-03
AU2002252470B2 (en) 2008-05-22
CA2440713A1 (en) 2002-10-03
AR033444A1 (es) 2003-12-17
MXPA03008762A (es) 2004-02-18
EP1372392A4 (en) 2004-06-23
EP1372392A1 (en) 2004-01-02

Similar Documents

Publication Publication Date Title
AU2002252470B2 (en) Nicotine-containing oral dosage form
US20040101543A1 (en) Nicotine-containing oral dosage form
AU2003267268B2 (en) Modified release oral dosage form
AU2002252470A1 (en) Nicotine-containing oral dosage form
US20210093563A1 (en) Medicinal delivery system and related methods
AU776019B2 (en) Medicated chewing gum delivery system for nicotine
KR101414063B1 (ko) 완충제로서 트로메타몰을 포함하는, 니코틴의 구강내 전달을 위한 피복된 약제학적 제품
US20070014887A1 (en) Medicated chewing gum delivery system for nicotine
KR20100017820A (ko) 아미노산으로 완충된 경구 니코틴 제형
CN110621307A (zh) 含有烟碱的口香糖组合物
KR102239291B1 (ko) 타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
AU2008202048A1 (en) Nicotine-containing oral dosage form
AU2012241150B2 (en) Medicinal delivery system and related methods
JUNO et al. PHARMACEUTICAL SCIENCES

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C12 Rejection of a patent application after its publication
RJ01 Rejection of invention patent application after publication